Furthermore, GFHPD consumption, as well as anti-EGFR Ab treatment, seems to be associated with a low-energetic colonic metabolism evoked by a loss of OXPHOS activity, resulting in inhibition of CRC progression in mice. The gene discussed is EGFR; the disease is colorectal carcinoma.